Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents.

[1]  E. Toone,et al.  High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors. , 2016, The Journal of antimicrobial chemotherapy.

[2]  Y. Yamaguchi,et al.  LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents. , 2016, ACS medicinal chemistry letters.

[3]  E. Toone,et al.  Drug design from the cryptic inhibitor envelope , 2016, Nature Communications.

[4]  G. Khodarahmi,et al.  Benzofuran as a promising scaffold for the synthesis of antimicrobial and antibreast cancer agents: A review , 2015, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[5]  Matthew D. Miller,et al.  Synthesis, Structure, and SAR of Tetrahydropyran-Based LpxC Inhibitors. , 2014, ACS medicinal chemistry letters.

[6]  N. Georgopapadakou.  Prospects for new antibacterials: can we do better? , 2014, Expert opinion on investigational drugs.

[7]  C. Walsh,et al.  Prospects for new antibiotics: a molecule-centered perspective , 2013, The Journal of Antibiotics.

[8]  Mark J. Mitton-Fry,et al.  Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents. , 2012, Bioorganic & medicinal chemistry letters.

[9]  Wei Zhang,et al.  Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives. , 2012, European journal of medicinal chemistry.

[10]  J. Warmus,et al.  Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC. , 2012, Bioorganic & medicinal chemistry letters.

[11]  V. Shanmugasundaram,et al.  Potent inhibitors of LpxC for the treatment of Gram-negative infections. , 2012, Journal of medicinal chemistry.

[12]  Lei Liu,et al.  Phase-Transfer-Catalyzed Intramolecular Hydroaryloxylation and Hydroamination of C≡C Triple Bonds: An Efficient Synthesis of Benzo[ b ]furan and 3-Methyleneisoindoline-1-one Derivatives , 2011 .

[13]  Pei Zhou,et al.  Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design. , 2011, Chemistry & biology.

[14]  C. Fierke,et al.  Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 . , 2011, Biochemistry.

[15]  L. Silver.  Challenges of Antibacterial Discovery , 2011, Clinical Microbiology Reviews.

[16]  W. Scheld,et al.  Newer antibacterial drugs for a new century , 2010, Expert opinion on investigational drugs.

[17]  Jean-Olivier Zirimwabagabo,et al.  A new cross-coupling-based synthesis of carpanone. , 2009, Organic letters.

[18]  H. Abdel‐Aziz,et al.  Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles. , 2009, European journal of medicinal chemistry.

[19]  S. Chandler,et al.  Antibacterial Activities and Characterization of Novel Inhibitors of LpxC , 2002, Antimicrobial Agents and Chemotherapy.

[20]  A. Patchett,et al.  Antibacterial Agents That Inhibit Lipid A Biosynthesis , 1996, Science.

[21]  C. Raetz,et al.  The envA Permeability/Cell Division Gene of Escherichia coli Encodes the Second Enzyme of Lipid A Biosynthesis , 1995, The Journal of Biological Chemistry.

[22]  Graham F Smith,et al.  Designing drugs to avoid toxicity. , 2011, Progress in medicinal chemistry.